Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral tegafur/uracil.

K Wellington1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|March 13, 2002
PubMed
Summary
This summary is machine-generated.

Oral tegafur/uracil demonstrated comparable efficacy to intravenous fluorouracil in metastatic colorectal cancer patients. This oral regimen offered a more favorable tolerability profile, with fewer adverse events like stomatitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Tegafur is an oral prodrug of fluorouracil, a key antineoplastic agent.
  • Uracil modulates fluorouracil activity when administered in combination.
  • Metastatic colorectal cancer (mCRC) treatment often involves intravenous fluorouracil-based chemotherapy.

Purpose of the Study:

  • To compare the efficacy and tolerability of oral tegafur/uracil plus calcium folinate with intravenous fluorouracil plus folinic acid in mCRC.
  • To evaluate oral tegafur/uracil in elderly patients with mCRC.
  • To assess oral tegafur/uracil as neoadjuvant therapy for rectal cancer.

Main Methods:

  • Two large, randomized, nonblind, multicenter trials (n=816 and n=380) compared oral tegafur/uracil with IV fluorouracil.

Related Experiment Videos

  • Dosage regimens included oral tegafur/uracil 300 mg/m(2)/day plus calcium folinate for 28 days every 35 days.
  • IV fluorouracil 425 mg/m(2)/day plus folinic acid for 5 days every 28 or 35 days was the comparator.

    • Main Results:

    • Median survival was approximately 12 months for both oral tegafur/uracil and IV fluorouracil groups.
    • Overall response rates were similar between oral tegafur/uracil (11-12%) and IV fluorouracil (9-15%).
    • Oral tegafur/uracil showed a significantly better tolerability profile, with less frequent stomatitis and hematological adverse events.

    Conclusions:

    • Oral tegafur/uracil is as effective as IV fluorouracil for metastatic colorectal cancer.
    • The oral regimen offers improved tolerability, making it a viable alternative treatment option.
    • Oral tegafur/uracil shows promise in elderly mCRC patients and as neoadjuvant therapy for rectal cancer.